Merck in collaboration with UCLPartners invites you to the standalone promotional webinar: ‘MS, Rethinking Tomorrow’ for Academic Health Science Networks (AHSNs) and the MS clinical community – developed by Merck in collaboration with the AAC Cladribine Working Group, led by UCLPartners on behalf of the AHSN Network.

WEDNESDAY 30TH SEPTEMBER 2020, 5PM-6PM
The role of AAC-Designated Cladribine Oral Tablets in re-establishing MS services after COVID-19

In this promotional webinar we will explore the challenges in getting patients back on to DMT treatment during the COVID-19 pandemic and look at the role of cladribine tablets in appropriate patients. Each panelist will deliver a short presentation, followed by a facilitated Q&A on the issues discussed.

SPEAKERS
INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – LONDON PERSPECTIVE

Dr Heather Wilson, Consultant Neurologist, National Hospital for Neurology and Neurosurgery, London

INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – NOTTINGHAM UNIVERSITY HOSPITAL PERSPECTIVE

Dr Nikos Evangelou, Consultant Neurologist & Associate Clinical Professor, Nottingham University Hospital

INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – SOUTH WEST PERSPECTIVE

Professor Jeremy Hobart, Consultant Neurologist, Plymouth Hospitals NHS Trust

Chaired by Dr Charlie Davie, Consultant Neurologist, UCLPartners

This standalone promotional webinar is aimed at individuals within AHSNs who have an interest in MS services and the MS clinical community, including MS neurologists, MS nurses and pharmacists.

This promotional webinar has been initiated, organised and funded by Merck in collaboration with UCLPartners.

Support
Have you completed the survey?
No, take the survey
Yes, log out